PhorMed, Inc., a clinical stage biopharmaceutical company founded in 2019, is developing a drug internally called RP-323 or 12-O-tetradecanoylphorbol-13-acetate (TPA) aka phorbol-12-myristate-13-acetate (PMA)... We are a biopharmaceutical company..
Relevance: 21.920729